The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Erin Bohula is an Associate Physician in Cardiovascular Medicine at Brigham and Women’s Hospital, Boston, MA, USA, an Investigator at the Thromboloysis in Myocardial Infarction Clinical Trials (TIMI) Study Group and an Assistant Professor at Harvard Medical School. Dr Bohula earned her DPhil in Molecular Biology from University of Oxford, Oxford, UK on a Rhodes Scholarship and her medical degree from Harvard Medical School, Boston, MA. Following training at the Brigham and Women’s Hospital, she received board certification in internal medicine, cardiology, and critical care medicine.
In her role as a TIMI Study Group Investigator, Dr Bohula studies pharmacologic interventions for cardiometabolic diseases, such as hyperlipidaemia, obesity and atherosclerotic cardiovascular disease. As a cardiac intensivist and researcher, she is interested in innovative therapies and devices for critically ill cardiovascular patients and was involved in creating the Critical Care Cardiology Trials Network, a North American research collaborative of cardiology critical care units (CICU). She was the recipient of the Eugene Braunwald Cardiovascular Medicine Physician Scientist Scholar Award in 2018 and the W. Proctor Harvey MD Young Teacher Award from the ACC in 2017.
Saint Luke’s Mid America Heart Institute, Kansas, USA
Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Dr. Kosiborod received training in clinical research, epidemiology, and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. Dr. Kosiborod has authored and co-authored over 250 peer-reviewed publications, including scientific statements and position documents. Dr. Kosiborod is involved in the leadership of multiple clinical trials and multi-center registries and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and cardiovascular disease.